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Background: The use of biomarkers has expanded considerably, as an alternative to questionnaire-based metrics of
environmental tobacco smoke (ETS); few studies have assessed the affect of such alternative metrics on diverse
respiratory outcomes in children, and we aimed to do so.
Methods: We evaluated various measures of birth-year ETS, in association with multiple respiratory endpoints early
years of life, in the novel context of a birth cohort at high risk for asthma. We administered questionnaires to
parents, both at the end of pregnancy and at one year of life, and measured cotinine in cord blood (CCot; in 275
children) and in urine (UCot; obtained at 12 months in 365 children), each by radioimmunoassay. Multiple logistic
regression was used to assess the association of the various metrics with recurrent wheeze at age 2 and with
bronchial hyperresponsiveness (BHR) and asthma at age 7.
Results: Self-reported 3rd trimester maternal smoking was associated with significantly increased risk for recurrent
wheeze at age 2 (odds ratio 3.5 [95% confidence interval = 1.2,10.7]); the risks associated with CCot and 3rd
trimester smoking in any family member were similar (OR 2.9 [1.2,7.0] and 2.6 [1.0,6.5], respectively). No metric of
maternal smoking at 12 months appeared to significantly influence the risk of recurrent wheeze at age 2, and no
metric of ETS at any time appeared to significantly influence risk of asthma or BHR at age 7.
Conclusions: Biomarker- and questionnaire-based assessment of ETS in early life lead to similar estimates of
ETS-associated risk of recurrent wheeze and asthma.
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Exposures that confer risk for incident childhood asthma
include early-life stressors and infections, allergens, out-
door pollutants, and tobacco smoke [1]. In our previous
work [2], we focused on the lattermost and demon-
strated that questionnaire-based exposure to environ-
mental tobacco smoke (ETS) at year 7, administered to
parents within a birth cohort of high-risk children, was
not a risk factor for asthma at year 7. An alternative to
questionnaire-based data is to examine cotinine as a di-
rect metric of exposure. A recent comprehensive meta-
analysis [3], which included studies of older children,* Correspondence: carlsten@mail.ubc.ca
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reproduction in any medium, provided the orconverted cotinine measures to approximate cigarette
dose as an alternative to comparing the effect of the
various metrics on risk estimates directly. However, few
studies have assessed the effect of multiple ETS expo-
sure metrics on diverse respiratory outcomes over a
number of years. We hypothesized that biomarker-based
assessment of ETS and questionnaire-based assessment
of ETS would lead to different estimates of ETS-
associated asthma risk. The purpose of the paper is to
compare questionnaire-based ETS estimates with bio-
markers of ETS, in terms of associated risk for recurrent
wheeze, physician-diagnosed asthma, and measures of
bronchial hyperresponsiveness (BHR), using a unique
birth cohort.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The cohort consisted of 545 children from Vancouver
and Winnipeg at high-risk of asthma, 380 (70%) of
whom were followed over 7 years. High-risk was defined
as having, according to parental report, at least one first-
degree relative with asthma or two first-degree relatives
with other IgE-mediated allergic disease (atopic derma-
titis, seasonal or perennial allergic rhinitis, or food al-
lergy). We successfully measured cotinine in cord blood
(CCot; in ng/ml) obtained at birth in 275 children and
urinary cotinine:creatine (UCot, in ng/mg) obtained at
12 months in 365 children, each by radioimmunoassay
kits (Brandeis University, Department of Biochemistry,
Waltham, MA). The limit of detection of cotinine is 200
pg/ml. As previously reported [4,5], questionnaire data
were obtained in person (via parents) during the third
trimester of pregnancy and at one, 2 and 7 years of age,
and asthma and BHR were determined at age 7. Asthma
was defined as at least 2 or more distinct episodes of
cough, each lasting at least 2 or more weeks, at least 2
distinct episodes of wheeze, each lasting at least one or
more weeks; plus at least 1 of the following: nocturnal
cough (at least once a week) in the absence of a cold,
hyperpnea-induced cough or wheeze at any time, or re-
sponse to treatment with beta-agonist and/or anti-
inflammatory drugs. Recurrent wheeze at age 2 was
defined as at least 3 episodes of wheezing in the past 12
months reported by questionnaire. Logistic regression,
with covariates as noted below, was used to determine
the odds ratio for a given outcome associated with ma-
ternal smoking during the 3rd trimester, any family
member smoking during the 3rd trimester, and measure-
ment of cord blood cotinine at the time of birth, as well
as maternal smoking, any family member smoking and
urinary cotinine and creatinine, at one year of age, as
detailed further in Table 1. Individual smoking was a
dichotomized variable whereas cotinine measures were
continuous variables. Only those children with data on
each of the ETS metrics for a given exposure window
were included. The fluxogram (Figure 1) summarizes the
flow of our study.
Results
Reported maternal smoking at any timepoint assessed
was infrequent (8% during the 3rd trimester and 9% at
one year of age). Amongst those mothers who smoked
during the 3rd trimester, the mean (± SD) number of
cigarettes per day was 10 (± 7). 69% of those reduced
smoking during pregnancy. The Pearson correlation (r)
between a positive self-report of maternal smoking du-
ring the third trimester of pregnancy and CCot was 0.89
(p < 0.0001). CCot ranged from 0 (below the detection
limit) to 330 ng/ml; UCot ranged from 0 (below the de-
tection limit) to 2821 ng/mg. The r between a positiveself-report of maternal smoking at 12 months and uri-
nary cotinine was 0.48 (p < 0.0001). The correlations be-
tween any family member reporting smoking during 3rd
trimester or at 12 months, and CCot or UCot (respect-
ively), were 0.52 (p < 0.0001) and 0.47 (p < 0.0001). The
r between UCot and CCot was 0.54 (p < 0.0001).
As noted in Table 1, the choice of ETS metric during a
given exposure time-frame influences the estimate of
asthma risk only modestly; within a given exposure
time-frame the various measures generally confer similar
risk for a given respiratory outcome. For exposures near
the time of birth, all 3 metrics were associated with sig-
nificantly increased risk for recurrent wheeze at year 2,
but none was associated with significant risk of wheeze
or asthma of the year 7 outcomes. Regarding the mea-
sures determined at 12 months, there is a trend towards
increased risk for recurrent wheeze at 2 years, with the
objective measure of UCot being associated with a bor-
derline significant risk for recurrent wheeze (OR 2.2,
[0.99, 4.7], p = 0.051). Regarding asthma and BHR at 7
years, no metric was significantly associated with risk.
There was a suggestion that self-reported metrics con-
ferred relative “protection” for asthma at 7 years (bor-
derline statistical significance) while the opposite trend
was apparent based on the biomarkers. We did sensiti-
vity analyses using alternate cutoffs for elevated CCOt
and UCot, based on prior literature [6,7], but this did
not appreciably change the results.
Discussion
In the 1980’s large cohort studies showed that ETS ex-
posure, assessed by parental questionnaire, was asso-
ciated with increased risk for BHR in children [8].
Subsequently, investigators moved to gathering biomar-
kers of exposure from the children themselves. Chil-
dren’s urinary cotinine was demonstrated as a biomarker
of risk for asthma and wheeze [9]. Subsequently, the use
of biomarkers for ETS has expanded considerably and
several reports have directly compared the various mea-
sures as exposure metrics [6,7,10], revealing complex dy-
namics dependent on several variables. In our initial
analysis of risk factors for asthma at age seven [2], we
were surprised to find that questionnaire data suggested
that maternal smoking was not a significant risk factor
and could be a significant “protective” factor. The
questionnaire-based data in the current study again sug-
gests “protection” from maternal smoking, though with
a less focused confidence interval due to a smaller sam-
ple size (in our previous paper [2] biomarkers were not
required for inclusion in analysis). As we speculate that
maternal smoking is unlikely to be truly protective, these
findings motivated our exploration of more objective
measurement of exposure, and our findings reinforce
that motivation.
Table 1 Risk of asthma, recurrent wheeze and bronchial hyperreactivity with various metrics of environmental
tobacco smoke
2 years 7 years
Recurrent wheeze Asthma Bronchial hyperreactivity





5/23 (21.7) 18/252 (7.1) 3.5 (1.2,10.7) p=0.025 4/50 (8.0) 19/229 (8.3) 0.5 (0.1,1.6) 11/146 (7.5) 9/112 (8.0) 0.9 (0.4,2.3)
Any family member smoking
(self-reported)
during 3rd trimester
11/23 (47.8) 60/252 (23.8) 2.9 (1.2,7.0) p=0.015 14/50 (28.0) 58/229 (25.3) 0.9 (0.4,1.9) 38/146 (26.0) 29/112 (25.9) 1.0 (0.6,1.8)
Cord blood cotinine above 50th
percentile
16/23 (69.6) 119/252 (47.2) 2.6 (1.0,6.5) p=0.045 31/50 (62.0) 106/229 (46.3) 1.7 (0.9,3.2) 74/146 (50.7) 51/112 (45.5) 1.2 (0.7,2.0)
Measures at
12 months
Maternal smoking (self-reported) at
12 months
4/33 (12.1) 29/332 (8.7) 1.3 (0.4,4.1) 5/71 (7.0) 28/299 (9.4) 0.3 (0.1,1.0) 15/188 (8.0) 15/150 (10.0) 0.8 (0.4,1.7)
Any family member smoking
(self-reported) at
12 months




23/33 (69.7) 167/332 (50.3) 2.2 (0.99,4.7) 43/71 (60.6) 149/299 (49.8) 1.2 (0.7,2.1) 94/188 (50.0) 79/150 (52.7) 0.9 (0.6,1.3)
BOLD indicates p < 0.05 frequency of exposure at given age amongst those with (“yes”) or without (“no”) given diagnosis.
* each model adjusted for group allocation (“intervention”) and for any baseline characteristic (race gender, history of asthma, maternal education, residence city, season, child’s atopic status) with p<0.05 upon being
entered in a stepwise manner.


















545 children recruited at birth; questionnaires administered to parents at 
birth and at year 2
380 children assessed at 7 year follow-up (personal and family 
characteristics of these were not different from the characteristics of those 
in original cohort*). Questionnaires and airway responsiveness assessed in 
all subjects; cord blood and/or urinary cotinine analyzed in 365.
Multiple logistic regression assessed the association of ETS (by 
questionnaire and by cotinine) with recurrent wheeze at age 2 and with 
bronchial hyperresponsiveness (BHR) and asthma at age 7
Figure 1 Flow chart of essential study features.
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data regarding maternal smoking from the period prior
to the 3rd trimester and sample size affecting the confi-
dence limits for the effect of various metrics. This is im-
portant because Neuman and colleagues [11] have
documented a time-dependency to ETS exposures du-
ring early life, though their analysis focused on pregnancy
versus post-pregnancy ETS rather than on trimester-
specific ETS. Duijts and colleagues [12] did look at
trimester-specific effects but for wheeze only (not asthma).
Note however that given our specific motivation to com-
pare questionnaire-based data versus that biological sam-
pling, the 3rd trimester would correspond most closely
with cord-blood at birth. Another potential limitation is
that concern for familial asthma risk led to behavioral
changes (decreased smoking) of some family members to
reduce the risk of asthma in their children, thus limiting
generalizability of our findings in this cohort of children at
high risk for asthma, relative to other cohorts with average
asthma risk and more typical smoking prevalence. Finally,
we did note that amongst those 31 children in the cohort
that had both frequent “colds”, defined as at least 3 per
year, the risk for wheeze at 2 years (45%) was higher thanin those with fewer colds (6% of these children had
wheeze at 2 years). Though we were underpowered for a
specific analysis of interactions between ETS and upper
respiratory tract infections, potential such interactions re-
main an important concern, as highlighted by Ciprandi
and others [13].
In spite of these limitations, our study is unique in
evaluating various measures of ETS, in association with
multiple respiratory endpoints; we believe that this is
further unique in the context of a birth cohort at high
risk for asthma but with modest maternal smoking rates.
In spite of self-reported maternal smoking occurring in
reportedly less than 10% of the families, this metric
appears to be the robust for predicting early life recur-
rent wheeze, and similar risk estimates for this endpoint
were noted when ETS was represented by either a
broader sampling of family members or by cord blood
cotinine. This latter similarity in risk is remarkable since
cotinine, while more comprehensively measuring inhaled
ETS (including that due to paternal and incidental expo-
sures), has a relatively short half-life of approximately 20
hours [14] and thus may not represent averaged expo-
sure over the specific time period.
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In conclusion, various metrics of ETS exposure focused
on the time of birth, but not those focused at 1 year of
age, seem to confer increased risk for recurrent wheeze
at 2 years, but none of these ETS metrics appear to con-
fer risk for later respiratory outcomes. As recent work
by others suggest [15], this pattern may be explained by
ETS exposure leading to transient inflammation in the
context of underdeveloped 2-year-old airways (precipi-
tating wheezing at age 2), rather than to changes result-
ing in persistently hyperreactive airways at age 7; ETS
exposure may be particularly influential in early-life
wheeze, but such influence may be less strong (relative
to other exposures that influence respiratory outcomes)
by 7 years of life in high risk children. Biomarker- and
questionnaire-based assessment of ETS in early life lead
to similar estimates of ETS-associated risk of recurrent
wheeze and asthma in this high-risk cohort.
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